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Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that is known to play a central role in lipid metabolism
and insulin sensitivity as well as inﬂammation and cell proliferation. According to the results obtained from studies on several
animalmodelsofgastrointestinalinﬂammation,PPARγ hasbeenimplicatedintheregulationoftheimmuneresponse,particularly
inﬂammation control, and has gained importance as a potential therapeutic target in the management of gastrointestinal
inﬂammation. In the present paper, we present the current knowledge on the role of PPARγ ligands in the gastrointestinal tract.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors belonging to the nuclear receptor
superfamily and have been initially described as molecular
targets for compounds that cause peroxisome proliferation
[1]. Thus far, 3 isotypes of PPARs (PPARα,P P A R δ (also
known as PPARβ), and PPARγ) have been found in various
species [2–5]. Of these, PPARγ proved to be a key tran-
scription factor involved in lipid metabolism and adipocyte
diﬀerentiation. In addition, recent studies suggest that
PPARγ may be involved in the control of inﬂammation and
especially modulation of the expression of various cytokines
in monocytes and macrophages [6, 7]. Regarding the anti-
inﬂammatory properties of PPARγ,P P A R γ activation has
been shown to antagonize the activity of activation protein-
1 (AP-1), Stat 1, and nuclear factor-κB( N F - κB), which are
known for positively controlling cytokine gene expression
[6].
PPARγ predominates the adipose tissue, large intestine,
macrophages, and monocytes [6, 8–10]. Recently, it was
demonstrated that 15-deoxy-Δ12, 14-prostaglandin J2 (15d-
PGJ2), and various polyunsaturated fatty acids have been
identiﬁed as natural receptor ligands of PPARγ. In addition,
thiazolidinediones such as troglitazone, pioglitazone, and
rosiglitazone, which are used as antidiabetic drugs, have
been developed as synthetic PPARγ ligands. The use of such
ligandshasallowedresearcherstounveilmanypotentialroles
of PPARs in pathological conditions, including atheroscle-
rosis, inﬂammation, and cancer. In this paper, we present
the current knowledge available on the role of PPARγ in the
gastrointestinal tract.
2.Esophagus and PPARγ
Few studies have examined the role of PPARγ in the
esophageal mucosa. PPARγ expression in the epithelium of
Barrett’s esophagus (BE) is elevated as compared to that in
the normal esophageal squamous epithelium [11]. Reﬂux of
gastric juice or bile acid into the esophagus causes injury to
the esophageal squamous epithelium, because of which the
injured esophageal mucosa is replaced by columnar epithe-
lium;thisentityiscalledBE.Importantly,BEisthemajorrisk
factor for esophageal adenocarcinoma. The PPARγ ligands
pioglitazone and ciglitazone when used alone inhibited
cell proliferation in OE33 cells derived from esophageal
adenocarcinoma [11, 12]; this result suggests that PPARγ
plays an important role in Barrett’s carcinogenesis and that
PPARγ ligands may be useful as new therapeutic agents
for the prevention and treatment of Barrett’s carcinoma.
However, because it has been reported that OE33-derived
transplantable adenocarcinoma was enhanced in vivo by sys-
temic PPARγ activation due to cell proliferation, the detailed
role of PPARγ in the esophagus remains controversial [11].2 PPAR Research
In regard to human esophageal squamous cell carcinoma
(SCC), PPARγ h a sb e e nf o u n dt ob ee x p r e s s e di nh u m a n
SCC cell lines such as TE-1, TE-2, TE-5, TE-7, TE-8,
TE-9, and TE-10 [13, 14]. Interestingly, PPARγ ligands
such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), and
troglitazone signiﬁcantly inhibited the proliferation of these
SCC cells in a dose-dependent manner [13]. On the other
hand, Terashita et al. reported that although PPARγ mRNA
expression was detectable in the majority of human SCC
tissuesandallthenormalesophagealmucosa,PPARγ mRNA
expression level was signiﬁcantly decreased in SCC tissues
compared to normal esophageal mucosa [14]. In their
clinicopathologicalstudies,PPARγ mRNAexpressionlevelin
the patients with esophageal SCC with extensive lymph node
metastasis was signiﬁcantly decreased compared with those
with less extensive lymph node metastasis. Thus, the role
of PPARγ remains controversial in esophageal SCC as well
as esophageal adenocarcinoma, and further examinations is
required to gain a better understanding of the role of PPARγ
in esophageal tumors.
3. Stomach andPPARγ
In several studies, it has been demonstrated that PPARγ
ligands reduced the extent of mucosal damage and inhib-
ited the inﬂammatory response to gastric inﬂammation
(Table 1). First, we demonstrated that pioglitazone, a speciﬁc
PPARγ ligand, ameliorated aspirin-induced injury to the
gastric mucosa in rats (Figure 1) and inhibited the increase
in neutrophil accumulation associated with gastric mucosal
TNF-α contents, which were measured by Enzyme-Linked
Immunosorbent Assay (ELISA) [15]. PPARγ has also been
implicated in the control of gastric mucosal damage induced
by ischemia-reperfusion injury [16]. Pioglitazone, rosiglita-
zone, troglitazone, and 15d-PGJ2 inhibited gastric mucosal
damage induced by ischemia-reperfusion injury through
the inhibition of cytokines expression such as TNF-α and
IL-1β, and the inhibition of the neutrophil accumulation
in the gastric mucosa [16–21]. Interestingly, regarding the
expression of intercellular adhesion molecule-1 (ICAM-1),
which played an important role in neutrophil inﬁltration
into gastric mucosa, the increased expression of ICAM-
1 after gastric ischemia reperfusion was also inhibited by
treatment with these PPARγ ligands [18, 21]. Thus, PPARγ
mediated the amelioration of the inﬂammatory responses
involved in acute gastric damage.
In gastric ulcer healing, it seems that the activation
of PPARγ ligands produces favorable eﬀects. Pioglitazone
accelerates the healing of acetic acid-induced gastric ulcers
by the triggering anti-inﬂammatory eﬀects, including the
suppression of interleukin (IL)-1β, tumor necrosis factor-
α (TNF-α, cyclooxygenase (COX)-2, and inducible nitric
oxide synthase (iNOS), and by increasing the expression of
heat shock protein 70 (HSP70) [23]. Brzozowski et al. also
demonstrated that pioglitazone accelerates the healing of
gastric ulcers induced by topical application of 100% ethanol
or water immersion and restraint stress [24]. In addition to
suppression of the proinﬂammatory cytokines TNF-α and
Table 1: Cytoprotective properties of PPARγ in experimental
model of gastric injuries.
Model PPARγ ligand References
Gastric Ulcer
(Acute gastric damage) Pioglitazone Naito et al. [15]
(H. pylori-induced
gastritis) Citiglitazone B. L. Slomiany and
A. Slomiany [39]
(Gastric ulcer Healing) Pioglitazone
Konturek et al.
[17], Brzozowski et





al. [23], Wada et al.
[21]
Rosiglitazone Villegas et al. [20],
Wada et al. [21]
Troglitazone Wada et al. [21]
15d-PGJ2 Takagi et al. [19]
interleukin-1β (IL-1β, pioglitazone enhanced angiogenesis
through increased expression of platelet endothelial cell
adhesion molecule-1 (PECAM-1)). Furthermore, Lahiri et
al. also reported that pioglitazone-induced activation of
PPARγ mediated gastric ulcer healing in rats, and this
pioglitazone-mediated gastroprotectiveeﬀectisalsoinvolved
in glucocorticoid receptor activation during chronic gastric
ulcer healing [22]. Hence, together the data suggest that
PPARγ is a novel therapeutic target molecule and PPARγ lig-
ands can be used as therapeutic agents for gastric ulcerative
lesion.
Interestingly, PPARγ plays a crucial role in gastric
mucosal injury in relation to H. pylori (Helicobacter pylori)
infection. As It has been well known that Helicobacter
pylori infection plays important role as the cause of chronic
gastritis [37] and as a deﬁnite carcinogen in gastric cancer
[38], understanding how PPARγ is involved in H. pylori
infectionmayleadtothedevelopmentoftherapeuticstrategy
for H. pylori infection. B. L. Slomiany and A. Slomiany
have demonstrated that H. pylori lipopolysaccharide- (LPS-)
elicited mucosal inﬂammatory responses were accompanied
by a massive epithelial cell apoptosis, upregulation of iNOS,
and COX-2 expression, and PPARγ ligand ciglitazone sup-
presses these gastric mucosal inﬂammatory responses and
may provide therapeutic beneﬁts such as the amelioration
of inﬂammation associated with H. pylori infection [39].
In fact, PPARγ expression in the gastric mucosa increases
with H. pylori infection and produces cytoprotective and
anti-inﬂammatory eﬀects in the gastric mucosa [40]. Fur-
thermore, Konturek et al. also have shown that PPARγ is
implicated in H. pylori-related gastric carcinogenesis and
that PPARγ agonists may have a therapeutic role in cancer
[41].Onexperimentalinvestigation,itwasfoundthatPPARγ
suppresses gastric carcinogenesis and that PPARγ ligands






































































































Figure 1: Eﬀect of increasing doses of pioglitazone on acute gastric mucosal injury induced by aspirin-HCl in rats (a) The eﬀect of
pioglitazone on tissue-associated myeloperoxidase (MPO) activity (b) and TNF-α content (c) induced by aspirin-HCl in the gastric mucosa.
TNF-α content and MPO activity in the gastric mucosa increased after aspirin administration. This increase in TNF-α content and MPO
activity was inhibited by pioglitazone treatment.
gastric carcinoma because they inhibit PPARγ-dependant
cell proliferation [42–44].
On the other hand, the importance of PPARγ polymor-
phism (Pro12Ala) has been reported. The PPARγ Pro12Ala
polymorphism has been reported to show decreased binding
to the promoter element and demonstrates weaker transac-
tivation of responsive promoters [45]. It has been reported
that PPARγ polymorphism (Pro12Ala) is associated with
various disease including diabetes, asthma, endometriosis,
polycystic ovary, and colorectal cancer [46–50]. Regarding to
gastric disease, this PPARγ polymorphism is associated with
not only gastric ulcer but also gastric adenocarcinoma [51–
53].
4.IntestineandPPARγ
In many studies, PPARγ has been reported to play a role in
thesmallandlargeintestine.Thisisprobablybecauseofhigh
PPARγ expression in the colon tissue. The high expression of
PPARγ seems to be related to intestinal bacteria. Dubuquoy
et al. showed that PPARγ expression in the colon tissue
was greater in conventional mice than in germ-free mice
[54]. More interestingly, they demonstrated that PPARγ
expression was weaker in the colon tissue of mice deleted for
the Toll-like receptor (TLR4) than in that of wild-type mice.
Furthermore, in colonic epithelial cells such as HT-29 and









Figure 2: (a) Image showing the appearance of the colon in a
mouse that was administered dextran sulfate sodium (DSS) (i) and
pioglitazone (ii). Loss and shortening of crypts, mucosal erosions,
inﬂammatory cell inﬁltration, and goblet cell depletion are seen in
(i). In (ii), smaller erosions are associated with less inﬂammatory
cell inﬁltration. Hematoxylin and eosin staining, ×10. Eﬀects of
pioglitazone on mRNA expression of TNF-α (b) and on DNA-
binding activity of NF-κB (c) in colonic tissues of mice that
were administered DSS. Reverse transcriptase-polymerase chain
reaction (RT-PCR), electrophoresis mobility shift assay (EMSA)
of sham-operated colon (lane 1), DSS-induced inﬂamed tissue
(lane 2), colon treated with 3mg/kg pioglitazone (lane 3), and
sham-operated colon treated with pioglitazone (lane 4). TNF-
α mRNA and NF-κB DNA-binding activity were upregulated in
inﬂamed colonic tissue (lane 2); this upregulation was suppressed
by pioglitazone administration (lane 3).
Table 2: Cytoprotective properties of PPARγ in experimental
model of the intestinal inﬂammation.
Model PPARγ ligand References
Ischemia/reperfusion
injury Rosiglitazone Nakajima et al.
[18]
Pioglitazone Naito et al. [25]
15d-PGJ2 Cuzzocrea et al.
[26]
DSS colitis Troglitazone Su et al. [27]
Rosiglitazone Saubemann et al.
[28]
Pioglitazone Takagi et al. [29],
Schaefer et al. [30]
CLA Bassaganya-Riera
et al. [31]
TNBS colitis Troglitazone Desreumaux et al.
[32]
Rosiglitazone S´ anchez-Hidalgo et
al. [33]
Pioglitazone Schaefer et al. [30]
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Rosiglitazone Sugawara et al.
[36]
DSS, dextran sodium sulphate; TNBS, 2,4,6-trinitrobenzene sulfonic acid;
15dPGJ2,15-deoxy-D12,14-prostaglandinJ2;CLA,conjugatedlinoleicacid;
5-ASA, 5-aminosalycilic acid; IL-10 KO, interleukin 10 knockout mice.
of the presence of LPSs [55]. These data indicate that the role
of bacteria-derived LPS in the regulation of PPAR expression
is more crucial in the colon tissue than in other parts of the
gastrointestinal tract.
With regard to the anti-inﬂammatory properties of P
PPARγ in intestinal inﬂammation, the therapeutic eﬃcacy
of PPARγ ligands has been evaluated in various diﬀerent
models of intestinal inﬂammation (Table 2). To determine
the role of PPARγ in intestinal ischemia-reperfusion injury,
Nakajima et al. [18] used PPARγ-deﬁcient mice and the
PPARγ agonist rosiglitazone. They demonstrated the dra-
matic protective eﬀects of rosiglitazone on both local and
remote organ injury after intestinal ischemia-reperfusion
injury and showed that the endogenous absence of PPARγ
leads to aggravated injury in this model. In several studies,
it has been demonstrated that the activation of PPARγ
by PPARγ ligands inhibited intestinal ischemia-reperfusion
injury[25,26,56].OnepossiblemechanismbywhichPPARγ
activation helps in protection against ischemia-reperfusionPPAR Research 5
injury is through the inhibition of NF-κB-mediated tran-
scription. The inhibition of NF-κB activation was conﬁrmed
by several approaches, including electrophoretic mobility
shift assays, immunohistochemistry using a phosphorylation
state-speciﬁc antibody for IκB, and mRNA levels of TNF-α
and intercellular adhesion molecule-1 (ICAM-1), which are
downstream targets of NF-κB.
Inﬂammatory bowel diseases (IBDs) such as ulcerative
colitis (UC) and Crohn’s disease (CD) constitute chronic
and recurrent intestinal inﬂammatory disorders; the precise
pathogenesis of these disorders remains unknown [57].
Therefore, it is very important to identify novel therapeutic
molecules for IBDs. In this regard, PPARγ may be a novel
therapeutic target. Su et al. showed that PPARγ ligands
markedly reduced colonic inﬂammation in a mouse model
of IBD [27]. We also reported that pioglitazone had a
protective eﬀect against murine dextran sulfate sodium-
(DSS-) induced colitis; a model of colitis induced in this
manneris commonlyusedasaUCmodel inassociation with
inhibition of the NF-κB-cytokine cascade [29]( Figure 2). In
mice, overexpression of PPARγ by an adenoviral construct in
mucosal epithelial cells was associated with amelioration of
experimental inﬂammation [58], and this study supports the
hypothesis that the upregulation of PPARγ expression itself
may have a protective eﬀect against colitis. In another study,
in which colitis was induced by trinitrobenzene sulfonic acid
(TNBS) and used as a CD model, PPARγ ligands such as
pioglitazone [30], rosiglitazone [33], and troglitazone [32]
inhibited the development of the intestinal inﬂammation.
DSS-induced and TNBS-induced colitis are widely used
models of chemically induced intestinal inﬂammation. In
studies on immune-reactive cells in the intestinal tissue of
UC and CD patients, it has been demonstrated that the
deregulatedimmuneresponseplaysacrucialroleintheonset
of IBD. Therefore, other types of colitis models are widely
used, including a transfer colitis model produced by transfer
of a T-cell population (CD4+CD45RBhigh T cells) that lacks
regulatory cells into an immunodeﬁcient host, spontaneous
colitis model such as the SAMP/Yit mouse, and genetic
colitis model such as interleukin IL-10-deﬁcient mice. In
a previous study, it was found that rosiglitazone delayed
the onset of colitis in IL-10-deﬁcient mice [35]. Further, it
was also found that crypt hyperplasia, caused by increased
mitotic activity of crypt epithelial cells, was also delayed by
rosiglitazone accompanied by the decreased expression of
interferon-γ (IFN-γ), IL-17, TNF-α, and iNOS in the colon.
Sugawara et al. have identiﬁed PPARγ as a CD susceptibility
gene in both mice and humans [36]. The administration of
rosiglitazone inhibited SAMP/Yit ileitis through regulation
of PPARγ activity in the crypts of the small intestine.
With regard to the relation between immune cells and
PPARγ, it has been reported that PPARγ ligands modulate
dendritic cell (DC) function to elicit the development of
anergic CD4+ T cells [59]. Hontecillas and Bassaganya-
Riera demonstrated that eﬀector CD4+ cell function was
downregulated by activated regulatory T cells (Tregs), which
w e r ea c t i v a t e db ye n d o g e n o u s l yp r o d u c e dP P A R γ [60]. In
fact,theyalsoshowedthatPPARγ deﬁciencyinTregsimpairs
the ability of Tregs to prevent T-cell transfer-induced colitis.
With regard to the CD4+ transfer colitis model, Bassaganya-
Riera et al. showed that conjugated linoleic acid ameliorated
colitis [31].
Thus, PPARγ ligands reduced mucosal damage and
prevented or downregulated the inﬂammatory response in
several murine models of intestinal inﬂammation. These
anti-inﬂammatory eﬀects suggest that PPARγ agonists may
provide a novel therapeutic approach for treating IBD.
In fact, rosiglitazone produced beneﬁcial eﬀects in the
treatment of UC in an open-label trial [61]. In this study,
rosiglitazonetreatmentforUCpatientsrefractorytoconven-
tional treatment yielded a decrease in disease activity index
score. Although the results of this pilot study are yet to be
conﬁrmed, PPARγ ligands may be novel therapeutic agents
for treating IBD.
More interestingly, Rousseaux et al. showed that the
therapeutic eﬀect of 5-aminosalicylic acid (5-ASA) may be
mediated by PPARγ [34]. Heterozygous PPARγ-knockout
mice were refractory to 5-ASA treatment, and 5-ASA directly
induced PPARγ expression in colonic epithelial cells in vitro.
Although 5-ASA is one of the conventional agents uses
for IBD treatment, the precise mechanism underlying the
protective eﬀect of 5-ASA remained unclear. These data
reveal that PPARγ is a target of 5-ASA; this ﬁnding underlies
the anti-inﬂammatory eﬀects produced in the colon.
Many studies have investigated the relation between
PPARγ and colon cancer. PPARγ is expressed at high levels
in primary colon tumors and colon cancer cell lines [62].
On the other hand, PPARγ ligands cause withdrawal of
colon cancer cell lines from the cell cycle, inhibit cell
growth, and promote diﬀerentiation [63, 64]. Based on
these ﬁnding, it appears as if PPARγ may be exerting some
other actions rather than regulating tumor growth. One
possibility is that PPARγ expression by the tumor may
program these cells to be less immunogenic or possibly
lead to the secretion of molecules that would end up
promoting tumor growth. Osawa et al. recently showed that
continuous feeding of pioglitazone reduced the aberrant
crypt foci formation and notably suppressed colon tumors
[65]. Although there is a contradictory study in which
APCmin/+ mice showed an increased number of polyps when
subjected to a PPARγ agonist [66], many research studies
have shown that PPARγ agonists seem to have inhibitory
eﬀects on the proliferation of colon cancer cells. PPARγ
ligands may represent a new group of biological agents that
can be used for the management of colon cancer.
5. Conclusion
In this paper, we focused on the therapeutic eﬀect of PPARγ
agonists in gastrointestinal inﬂammation. We performed
studies using several animal models of gastrointestinal
inﬂammation and accumulated evidence suggesting that
PPARγ plays a crucial role in gastrointestinal inﬂammation.
It was found that PPARγ ligand therapy reduced a wide
variety of inﬂammatory indices in diﬀerent animal models,
but the underlying mechanism by which PPARγ activation
produces these eﬀects was not fully established. We expect6 PPAR Research
thattheprecisemechanismbywhichPPARγ ligandsproduce
anti-inﬂammatory properties will be clariﬁed in the near
future.
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